Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China

Table 1 Key inputs for the Markov model

Model inputs	Value	Distribution	Low	High	Source
Direct costs per cycle
Abemaciclib	748.90	GAMMA	524.23	748.90	MENET
Letrozole	11.66	GAMMA	8.87	112.14	MENET
Follow-up visit for 1 to 2 years	125.42	GAMMA	100.34	150.51	Health care document
Follow-up visit for 3 to 5 years	73.16	GAMMA	58.53	87.80	Health care document
Follow-up visit after 5 years	24.39	GAMMA	19.51	29.51	Health care document
Administration	72.64	GAMMA	58.11	87.17	Health care document
Treatment for nonmetastatic recurrences	476.80	GAMMA	381.44	572.15	[27], MENET
Treatment for metastatic recurrence	444.00	GAMMA	355.20	532.80	[27], MENET
End-of-life care	2,689.86	GAMMA	1,596.00	2,394.00	[28]
Costs of AEs per cycle
Diarrhea	0.42	GAMMA	0.33	0.50	Expert opinion, MENET
Neutropenia	8.61	GAMMA	6.89	10.34	Expert opinion, MENET
Lymphopenia	3.57	GAMMA	2.85	4.28	Expert opinion, MENET
Risk of AEs in ABE + ET
Diarrhea	0.078	BETA	0.070	0.086	monarchE trial
Neutropenia	0.196	BETA	0.176	0.216	monarchE trial
Lymphopenia	0.054	BETA	0.049	0.059	monarchE trial
Health state utility (per year)
iDFS	0.965	BETA	0.744	0.980	[23, 41, 42]
Nonmetastatic	0.766	BETA	0.725	0.780	[19, 23, 42]
Remission	0.850	BETA	0.700	0.850	[19, 43]
Distant metastases	0.642	BETA	0.615	0.690	[19, 23, 41]
Disutilities of AEs (per year)
Diarrhea	0.103	BETA	0.124	0.082	[32]
Neutropenia	0.090	BETA	0.108	0.072	[31]
Lymphopenia	0.090	BETA	0.108	0.072	[31]
AEs duration (days)
Diarrhea	2	CONSTANT	/	/	[44]
Neutropenia	2	CONSTANT	/	/	[31]
Lymphopenia	2	CONSTANT	/	/	[31]
Cost discount rate	5%	CONSTANT	0%	8%	[45]
Outcome discount rate	5%	CONSTANT	0%	8%	[45]

Experts here refer to two clinical oncologist experts in China with more than 10 years of clinical experience in the treatment of breast cancer
AE: adverse event; ABE + ET: abemaciclib + endocrine therapy; iDFS: invasive disease-free survival

ISSN: 1478-7547